1445A SOUTH 50TH STREET, RICHMOND, CA
Announces Pricing of Upsized $115.0 Million Public Offering
BioAge to Expand BGE-102 Use, Starts Diabetic Macular Edema Trial in 2026
BioAge Reveals Positive Phase 1 Results for BGE-102 with Potential in Cardiovascular Risk Reduction
Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Reports Second Quarter 2025 Financial Results and Provides Business Updates
Submission of Matters to a Vote of Security Holders
Other Events
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-1MEF